Equities research analysts predict that NeoGenomics, Inc. (NASDAQ:NEO) will announce $0.05 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for NeoGenomics’ earnings. The lowest EPS estimate is $0.03 and the highest is $0.07. NeoGenomics reported earnings of $0.04 per share in the same quarter last year, which suggests a positive year over year growth rate of 25%. The business is expected to report its next earnings results before the market opens on Tuesday, April 30th.
On average, analysts expect that NeoGenomics will report full-year earnings of $0.24 per share for the current year, with EPS estimates ranging from $0.22 to $0.25. For the next fiscal year, analysts anticipate that the business will post earnings of $0.35 per share, with EPS estimates ranging from $0.29 to $0.41. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow NeoGenomics.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, February 19th. The medical research company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. NeoGenomics had a net margin of 0.95% and a return on equity of 2.25%. The company had revenue of $76.50 million during the quarter, compared to analyst estimates of $71.29 million. During the same quarter last year, the business posted $0.05 EPS. The firm’s revenue for the quarter was up 24.6% on a year-over-year basis.
Shares of NEO opened at $19.66 on Thursday. NeoGenomics has a 1-year low of $9.08 and a 1-year high of $22.17. The stock has a market cap of $1.86 billion, a P/E ratio of 151.23 and a beta of 0.93. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.70 and a quick ratio of 1.56.
In other news, Director Raymond R. Hipp sold 18,889 shares of NeoGenomics stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $18.90, for a total value of $357,002.10. Following the transaction, the director now owns 297,580 shares of the company’s stock, valued at approximately $5,624,262. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Steven C. Jones sold 14,621 shares of NeoGenomics stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $19.24, for a total transaction of $281,308.04. Following the completion of the transaction, the executive vice president now directly owns 241,815 shares in the company, valued at approximately $4,652,520.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 263,524 shares of company stock worth $5,019,496. Insiders own 12.20% of the company’s stock.
Several institutional investors have recently modified their holdings of NEO. JPMorgan Chase & Co. grew its position in shares of NeoGenomics by 423.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 60,259 shares of the medical research company’s stock worth $925,000 after buying an additional 48,754 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of NeoGenomics in the 3rd quarter worth approximately $224,000. Bank of New York Mellon Corp grew its position in shares of NeoGenomics by 26.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 882,244 shares of the medical research company’s stock worth $13,543,000 after buying an additional 182,172 shares during the last quarter. BlackRock Inc. grew its position in shares of NeoGenomics by 22.4% in the 3rd quarter. BlackRock Inc. now owns 5,079,026 shares of the medical research company’s stock worth $77,960,000 after buying an additional 929,697 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in NeoGenomics by 28.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 965,790 shares of the medical research company’s stock worth $14,825,000 after purchasing an additional 212,937 shares during the last quarter. 77.00% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: Buyback For Investors Defined
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.